183786-23-4 Usage
Uses
Used in Pharmaceutical Research and Development:
3-Piperidinecarboxylic acid, 2-methyl-, methyl ester (9CI) is utilized as an intermediate in the production of various pharmaceuticals. Its role in this application is attributed to its ability to be a precursor in the synthesis of drug molecules, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Piperidinecarboxylic acid, 2-methyl-, methyl ester (9CI) serves as a building block for the synthesis of a variety of organic compounds. Its structural properties make it a valuable component in creating complex organic molecules for various applications, including but not limited to chemical research and the production of specialty chemicals.
Used in Chemical Industry:
3-Piperidinecarboxylic acid, 2-methyl-, methyl ester (9CI) is also employed in the chemical industry for its versatile applications. Its use extends beyond pharmaceuticals to include the creation of intermediates for other chemical processes, highlighting its importance in the broader scope of chemical manufacturing and innovation.
Check Digit Verification of cas no
The CAS Registry Mumber 183786-23-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,7,8 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 183786-23:
(8*1)+(7*8)+(6*3)+(5*7)+(4*8)+(3*6)+(2*2)+(1*3)=174
174 % 10 = 4
So 183786-23-4 is a valid CAS Registry Number.
183786-23-4Relevant articles and documents
Design and Synthesis of 56 Shape-Diverse 3D Fragments
Atobe, Masakazu,Blakemore, David C.,Bond, Paul S.,Chan, Ngai S.,De Fusco, Claudia,Downes, Thomas D.,Firth, James D.,Hubbard, Roderick E.,Jones, S. Paul,Klein, Hanna F.,O'Brien, Peter,Roughley, Stephen D.,Vidler, Lewis R.,Waddelove, Laura,Whatton, Maria Ann,Wheldon, Mary C.,Woolford, Alison J.-A.,Wrigley, Gail L.
supporting information, (2020/07/13)
Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.
